Cone Health Women's Hospital

Mission Bio's Tapestri® Platform Used to Identify Hidden HIV-infected Cells in Nature Paper

Retrieved on: 
Vendredi, janvier 6, 2023
Harvard Medical School, MIT, Memory, MD, Research, Infection, HIV, Proteogenomics, DNA, Phenotype, SAN, Immunotherapy, Disease, Patient, Genome, Cell, Harvard University, Massachusetts General Hospital, MGH, Ragon Institute, Cone Health Women's Hospital, Hospital, Doctor of Philosophy, Vaccine, Brigham, Viremia, Medicine, Nature

SOUTH SAN FRANCISCO, Calif., Jan. 6, 2023 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced a new publication in Nature from researchers at the Ragon Institute of MGH, MIT, and Harvard and Brigham and Women's Hospital using Mission Bio's Tapestri® Platform to identify phenotypic signatures of hidden human immunodeficiency virus 1 (HIV-1)-infected immune cells that allow the virus to evade immune response. The team utilized Tapestri®'s proteogenomics capabilities to detect HIV DNA and corresponding surface markers on patients' memory CD4+ T cells for the first time, as well as to develop a fingerprint for latent infection that may guide new treatment approaches.

Key Points: 
  • Previous research has suggested that host immune cells can slowly deplete these reservoir cells, lending hope to the idea that immunotherapy approaches could someday be used to treat disease.
  • In the new paper, the Boston-based teams used single-cell proteogenomic profiling on the Tapestri® Platform to simultaneously evaluate HIV DNA and the phenotype of single unmanipulated, patient-derived cells.
  • "This new paper demonstrates the versatility of the Tapestri® Platform," said Todd Druley, MD, PhD, Chief Medical Officer of Mission Bio.
  • The paper, " Phenotypic signatures of immune selection in HIV-1 reservoir cells ," published on January 4 in Nature.

Serum Osmolality Disorders -- Importance, Evaluation and Treatment, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Mercredi, janvier 4, 2023
Electrolyte, Hospital, Patient, Brain, Treatment, Harvard Medical School, Fracture, Cone Health Women's Hospital, Hyponatremia, Evaluation, FASN, Diagnosis, Risk, Urine, Epidemiology, Food, Serum, MBA, Falls, MB, Hypercorrection, Medical device, Pharmaceutical industry, Medicine, BCH, Brigham, Nephrology

TORONTO, Ontario, Jan. 4, 2023 /PRNewswire-PRWeb/ -- Hyponatremia is a common condition in both hospitalized patients and in the community. It is associated with multiple adverse outcomes including an increased risk of falls and fractures which can be particularly devastating for elderly patients. In addition, hyponatremia in hospitalized patients has been associated with prolonged hospital stays and higher in-hospital mortality. Thus, the ability to accurately diagnose the cause of hyponatremia as well as determine the proper course of treatment is vital. Measurement of the serum and urine osmolality plays a key role in the management of patients with hyponatremia. The serum sodium level is a surrogate marker of the serum osmolality but has important limitations and cannot take the place of osmolality testing in making an initial diagnosis. Serial measurements of the urine osmolality and electrolytes is necessary to guide the treatment of hyponatremia as the character of the urine can change in response to fluid and diuretic administration.

Key Points: 
  • The featured speakers will discuss the specific roles that laboratory tests including urine and serum osmolality play in guiding clinical care.
  • Measurement of the serum and urine osmolality plays a key role in the management of patients with hyponatremia.
  • The serum sodium level is a surrogate marker of the serum osmolality but has important limitations and cannot take the place of osmolality testing in making an initial diagnosis.
  • For more information, or to register for this event, visit Serum Osmolality Disorders — Importance, Evaluation and Treatment .

Protillion Biosciences Raises $18 Million Series A Financing Led by ARCH Venture Partners and Illumina Ventures

Retrieved on: 
Lundi, décembre 19, 2022
Molecular biology, Computational biology, Wyss Institute for Biologically Inspired Engineering, Cone Health Women's Hospital, Drug discovery, Harvard University, MD Anderson Cancer Center, Hospital, Innovation, Science, Wyss Institute, Stanford University School of Medicine, Illumina, Inc., Stanford University, Protein engineering, Genome, Harvard Medical School, Partnership, Therapy, ARCH, Fine chemical, Pharmaceutical industry, Illumina, Brigham

BURLINGAME, Calif., Dec. 19, 2022 /PRNewswire/ -- Protillion Biosciences, a privately held biotech company working to identify and optimize new protein therapeutics and accelerate biologic research and development productivity, today announced the completion of an $18 million Series A financing from ARCH Venture Partners and Illumina Ventures. The Company's platform enables its commercial drug discovery partners to perform true quantitative analysis on complete protein libraries, producing actionable insights in days; a process that can take months using current industry best practices. Protillion's proprietary technology can generate and analyze massive experimental datasets at perfect amino acid resolution, enabling novel machine-learning approaches to antibody and binder discovery.

Key Points: 
  • BURLINGAME, Calif., Dec. 19, 2022 /PRNewswire/ -- Protillion Biosciences, a privately held biotech company working to identify and optimize new protein therapeutics and accelerate biologic research and development productivity, today announced the completion of an $18 million Series A financing from ARCH Venture Partners and Illumina Ventures.
  • Protillion is actively identifying opportunities to supercharge discovery processes for potential pharma partners through its cutting-edge technology.
  • ARCH Venture Partners invests in advanced technology companies and is one of the largest early-stage technology venture firms in the United States.
  • Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina, with the vision to unlock the power of the genome.

Political Hate Targeting Vulnerable Communities and Healthcare Workers, and Bomb Threats Against Boston Children's Hospital Prompt Condemnation from MNA Board of Directors

Retrieved on: 
Jeudi, décembre 15, 2022
Cone Health Women's Hospital, Supreme court, MNA, Children's Hospital, Patient, Nursing, Legislature, Hospital, Workplace, Child, Commonwealth, Reproductive rights, Caregiver, Multimedia, Safety, Violence, Health, Hatred, Supreme Court of the United States, Religion, Medicine, Boston Children's Hospital, Brigham

"Above all else, our duty as nurses and healthcare professionals is to protect the health and safety of our patients.

Key Points: 
  • "Above all else, our duty as nurses and healthcare professionals is to protect the health and safety of our patients.
  • The highly charged political environment whether bomb threats at Boston Children's Hospital, white supremacists outside Brigham and Women's Hospital, or attacks on reproductive rights is obstructing healthcare access, endangering lives, and further harming caregivers already exploited by a broken healthcare system.
  • The bomb threats and hate messages sent to Boston Children's Hospital are despicable for their intent and their impact.
  • As union members we will use our collective strength to defeat political hate and eliminate violence in healthcare."

Maternova Grows Product Leadership Team with Two Strategic Hires

Retrieved on: 
Mercredi, décembre 7, 2022
General Health, Health, Other Health, Cone Health Women's Hospital, UX, Mother, Columbia University, Rutgers University, Carnegie Mellon University, Head, ETS, Ideation, Research, BookBub, Virginia Commonwealth University, Ladder, Hospital, Engineering, Infant, Mortality, Health, Marketing, Educational Testing Service, Molly, Organization, Management, Brigham

Maternova, Inc. , accelerating advances in maternal and infant health through innovative, accessible solutions, today announced the expansion of their product leadership team with the appointment of Molly Baab as Chief Product Officer and head of digital growth and Juan Rafael Lopez as Director of Product.

Key Points: 
  • Maternova, Inc. , accelerating advances in maternal and infant health through innovative, accessible solutions, today announced the expansion of their product leadership team with the appointment of Molly Baab as Chief Product Officer and head of digital growth and Juan Rafael Lopez as Director of Product.
  • Maternova fast-tracks the commercialization of lifesaving maternal and newborn medical devices and diagnostics, prioritizing low- and middle-income countries and humanitarian settings.
  • Having a seamless, intuitive digital interaction is key to our business model," said Meg Wirth, Founder and President of Maternova.
  • As Chief Product Officer at Maternova, she will have responsibility for its overall product strategy and marketing plan, product development roadmap and digital growth.

Dentons Global Advisors Announces Expansion of Health Offering

Retrieved on: 
Lundi, décembre 12, 2022
ASG, Partner, Dubai Healthcare City, Cone Health Women's Hospital, Johns Hopkins Aramco Healthcare, Institute of Systems Science, Internet, Albright Stonebridge Group, MD, Johns Hopkins Medicine International, Partnership, Stony Brook University Hospital, WellSpan Health, Science, CSC, Johns Hopkins School of Medicine, Medicine, Cambridge Health Alliance, Government, Running, Partners Harvard Medical International, Medco Health Solutions, Boston Children's Hospital, Hospital, Dentons, Principal, Information technology, Healthcare, Management, Pharmaceutical industry, Saudi Aramco, Brigham

WASHINGTON, Dec. 12, 2022 /PRNewswire/ -- Dentons Global Advisors, an elite multidisciplinary advisory firm, today announced an expanded suite of services and products focused on developing the capacity of healthcare delivery organizations, enhancing their standards of care and improving patient outcomes. The leadership team comprises prominent figures from the medical field with expertise in the science, medicine, infrastructure, technology, personnel and financing needs of healthcare ecosystems. Mehul Mehta, MD has been appointed Principal and Chair of the Health Solutions practice. Additionally, Mohan Chellappa, MD, Riaz Adamjee and Bruce Solomon have joined as Partners.

Key Points: 
  • "We are assembling the best talent in the field to move at speed and at scale in this critical area," said Edward Reilly, Chief Executive Officer at Dentons Global Advisors.
  • "By combining Dentons Global Advisors' global footprint and cross-functional capabilities with the subject matter expertise of this all-star team, we are uniquely positioned to assist healthcare systems, governments, the public interest community and private capital in improving healthcare outcomes."
  • This is a significant expansion of services for Dentons Global Advisors, which provides integrated strategic counsel and support for clients facing complex opportunities and challenges spanning commercial, reputational, financial, regulatory and governance dimensions.
  • Dentons Global Advisors is an expert-led advisory firm that provides integrated solutions for clients in an increasingly complex, regulated and interconnected business environment.

Aetion Leads Cross Industry Initiative to Understand Strengths and Limitations of Regulatory Use of Real-World Evidence

Retrieved on: 
Mardi, novembre 29, 2022
Real-World Evidence, COVID-19, AstraZeneca, Public health, Friends, Hospital, AbbVie, Multimedia, Harvard Medical School, Safety, Real world evidence, Friends of Cancer Research, Health, Initiative, Coalition, Isabella Tree, Reagan-Udall Foundation, Aetion, Cone Health Women's Hospital, Epidemiology, RWE, Baylor College of Medicine, Health policy, CARE, RCT, Pharmaceutical industry, Bayer, Brigham, Tempus, Pfizer

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced the launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. The first phase of the Initiative will focus on oncology and involves a group of diverse partners including AbbVie, Amgen, AstraZeneca, Bayer, Baylor College of Medicine, Brigham and Women's Hospital and Harvard Medical School, ConcertAI, Duke-Margolis Center for Health Policy, Friends of Cancer Research, Gilead, Loopback Analytics, Pfizer, Reagan-Udall Foundation, Tempus, TriNetX, and xCures.

Key Points: 
  • Using the Aetion Evidence Platform, the Initiative will help identify when and how RWE can support the goals of advancing efficient access to medication and improving patient care.
  • "Data quality, accessibility, and analytical tools are progressing at a rapid pace," said Carolyn Magill, Chief Executive Officer at Aetion.
  • "We and our partners launched the Aetion CARE Initiative to advance global alignment on scientific methodologies to create real-world evidence and aid in its interpretation."
  • Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies.

Aetion Leads Cross Industry Initiative to Understand Strengths and Limitations of Regulatory Use of Real-World Evidence

Retrieved on: 
Mardi, novembre 29, 2022
Real-World Evidence, COVID-19, AstraZeneca, Public health, Friends, Hospital, AbbVie, Harvard Medical School, Safety, Real world evidence, Friends of Cancer Research, Health, Initiative, Coalition, Isabella Tree, Reagan-Udall Foundation, Aetion, Cone Health Women's Hospital, Epidemiology, RWE, Baylor College of Medicine, Health policy, CARE, RCT, Pharmaceutical industry, Bayer, Brigham, Tempus, Pfizer

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced the launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. The first phase of the Initiative will focus on oncology and involves a group of diverse partners including AbbVie, Amgen, AstraZeneca, Bayer, Baylor College of Medicine, Brigham and Women's Hospital and Harvard Medical School, ConcertAI, Duke-Margolis Center for Health Policy, Friends of Cancer Research, Gilead, Loopback Analytics, Pfizer, Reagan-Udall Foundation, Tempus, TriNetX, and xCures.

Key Points: 
  • Using the Aetion Evidence Platform, the Initiative will help identify when and how RWE can support the goals of advancing efficient access to medication and improving patient care.
  • "Data quality, accessibility, and analytical tools are progressing at a rapid pace," said Carolyn Magill, Chief Executive Officer at Aetion.
  • "We and our partners launched the Aetion CARE Initiative to advance global alignment on scientific methodologies to create real-world evidence and aid in its interpretation."
  • Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies.

AI Predicts Heart Disease Risk Using Single X-Ray

Retrieved on: 
Mardi, novembre 29, 2022
Radiation, Hypertension, Mass General Brigham, Deep learning, CXR, Stroke, Massachusetts General Hospital, American Heart Association, Mass, National academy, Hospital, National Cancer Institute, Risk, Patient, RSNA, Artificial intelligence, Prostate, Physician, Health, Cardiovascular disease, Education, Society, Type 2 diabetes, Collaborative writing, Radiological Society of North America, Moyamoya disease, Cone Health Women's Hospital, European Heart Journal: Cardiovascular Imaging, Randomized controlled trial, Disease, Cholesterol, Male, Death, Blood pressure, Radiology, Research, Fortis Healthcare, Lung, National Academy of Medicine, Smoking, Medical imaging, Medical device, Pharmaceutical industry

Deep learning is an advanced type of artificial intelligence (AI) that can be trained to search X-ray images to find patterns associated with disease.

Key Points: 
  • Deep learning is an advanced type of artificial intelligence (AI) that can be trained to search X-ray images to find patterns associated with disease.
  • Current guidelines recommend estimating 10-year risk of major adverse cardiovascular disease events to establish who should get a statin for primary prevention.
  • This risk is calculated using the atherosclerotic cardiovascular disease (ASCVD) risk score, a statistical model that considers a host of variables, including age, sex, race, systolic blood pressure, hypertension treatment, smoking, Type 2 diabetes and blood tests.
  • Dr. Weiss and a team of researchers trained a deep learning model using a single chest X-ray (CXR) input.

American College of Lifestyle Medicine Adds Digital Nutrition Solutions Innovator Metabite to its Corporate Roundtable

Retrieved on: 
Jeudi, novembre 17, 2022
Circadian rhythm, University, Hospital, Conditional sentence, Cone Health Women's Hospital, Obesity, ACLM, Degenerative disease, Student, Organization, Data collection, Type 2 diabetes, Entrepreneurship, Medicine, Athlete, Diet, Education, Research, API, Patient, Harvard University, Policy, Certification, American College, Communication, Food, Disease management, FACC, Exercise, Dietary supplement, Pharmaceutical industry, Dentistry, MD, Brigham

ST. LOUIS, Nov. 17, 2022 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine (ACLM) has announced the addition of digital nutrition solutions innovator Metabite to its Lifestyle Medicine Corporate Roundtable, a group of thought leaders and industry professionals who explore effective clinical innovations, activate marketing strategies, accelerate reimbursement and policy adoption, and pursue research and demonstrations of lifestyle medicine in practice. ACLM launched its Corporate Roundtable in 2016 and it now includes nearly 50 active member organizations in the lifestyle medicine ecosystem.

Key Points: 
  • The American College of Lifestyle Medicine (ACLM) has announced the addition of digital nutrition solutions innovator Metabite to its Lifestyle Medicine Corporate Roundtable.
  • ST. LOUIS, Nov. 17, 2022 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine (ACLM) has announced the addition of digital nutrition solutions innovator Metabite to its Lifestyle Medicine Corporate Roundtable, a group of thought leaders and industry professionals who explore effective clinical innovations, activate marketing strategies, accelerate reimbursement and policy adoption, and pursue research and demonstrations of lifestyle medicine in practice.
  • ACLM launched its Corporate Roundtable in 2016 and it now includes nearly 50 active member organizations in the lifestyle medicine ecosystem.
  • Lifestyle medicine certified clinicians are trained to apply evidence-based, whole-person, prescriptive lifestyle change to treat and, when used intensively, often reverse such conditions.